Neuromed Pharmaceuticals Ltd. has been granted the exclusive U.S. rights for the development and commercialization of OROS® Hydromorphone by ALZA Corporation.
An extended release formulation of a potent opioid analgesic undergoing Phase 3 clinical development, OROS® Hydromorphone was developed by ALZA and uses the OROS® PUSH-PULL™ delivery system to release the opioid at a controlled rate.
Approved in Germany and other European countries, OROS® Hydromorphone is marketed by Janssen-Cilag under the brand name JURNISTA®.
The terms of the agreement between Neuromed and ALZA includes the following:
- Neuromed will make an upfront payment of $30 million, additional regulatory milestone payments, and will pay royalties based on commercial sales of the product.
- Neuromed will develop and market the product in the U.S., while ALZA will retain the rights to develop and market the product in other countries.
- ALZA will manufacture the product for Neuromed as well as for other markets in which the product is sold.
Comment Preview